Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Goaweighon Feb 18, 2021 1:37am
199 Views
Post# 32593003

RE:RE:RE:Warrants

RE:RE:RE:WarrantsIt does take a moment to figure it out because 9 times out of 10 when one financial instrument is rolled back they are all rolled back, warrants and options. This time was differant.
So If anyone doesn't understand what they're buying when buying the warrants here it is again.




Goaweigh wrote: Your paying .18 per warrant and you require 9.5 of them to buy 1 share at $ 9.025
So 9.5 X .18 = $ 1.71 + $ 9.025 = $ 10.74
So you'll need the stock to go to $ 10.74 to break even on the .18 warrant
The analyst is calling it at US $ 15 or C $ 19
If it get's to C $ 19 the intrinsic value of the warrant would be $ 10 ( now $ 1.71 ) or 584 % 
so the warrant that's currently trading at .18 would go to $ 1.05
Meaning that if the stock hits $ 19.00 there's a 400 % return on the unlying stock
and a 584 % return on the warrant.

It works well for the warrant holder if the stock goes to $ 19 but not so well if it stalls at $ 10.74

You need more than a double just to break even !
I've been there before but never intensionally. LOL

Think I'd stick with the common.



westcoast1000 wrote: The deal is:

you need about 9.50 warrants to get one new share post R/S.

Do not be fooled by the price.




<< Previous
Bullboard Posts
Next >>